Kabi Stretches Adalimumab Presence To Nine Countries
Four Further Country Launches During Third Quarter
Executive Summary
Having started to roll out its Idacio adalimumab biosimilar in Europe earlier this year, Fresenius Kabi is now marketing the Humira rival in nine countries.